Respiratory Syncytial Virus (RSV) is a common virus that affects people of all ages. RSV has long posed a particular threat to both young children and older, vulnerable populations, often leading to respiratory infections, hospitalizations, and even death. Now, with the availability of new vaccines, healthcare providers aim to drastically reduce the impact of RSV, especially during its peak season in the fall and winter months.
Abrysvo was approved for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants from birth through 6 months of age. Abrysvo is approved for use at 32 through 36 weeks gestational age of pregnancy, and for patients ages 60 and older. (2) Select Avance Care locations have the Abrysvo vaccine available.
Arexvy was approved by the FDA in May for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older. (1)
Beyfortus was approved for the prevention of RSV lower respiratory tract disease in neonates and infants born during or entering their first RSV season, and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. (3) Due to unprecedented demand, Avance Care does not currently have Beyfortus vaccines available.
Contact your Avance Care location to see if they are offering the RSV vaccines, and learn more ways to prepare and protect your child from RSV.
Resources:
- https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine#:~:text=Arexvy%20is%20approved%20for%20the,years%20of%20age%20and%20older
- https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants
- https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers
